GlassScriptPhysician profile
James R Penn
NPI 1588094569
$19,448.26
in general payments reported to CMS, 2019-2025
34 companies · $9,322 in 2025
The $9,322 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $379 · 2021: $698 · 2022: $1,052 · 2023: $1,666 · 2024: $5,602 · 2025: $9,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,505 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,955 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,504.74 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,955.00 |
| Education | $129.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $8,736.57 | 2024-2025 | Voquezna |
| Abbvie INC. | $2,093.76 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,646.43 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,641.67 | 2019-2025 | Tremfya, Stelara |
| Qol Medical, LLC | $720.98 | 2021-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $594.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $531.61 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $524.64 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $434.27 | 2019-2024 | Linzess |
| Celgene Corporation | $403.22 | 2022-2024 | Zeposia |
| Lilly USA, LLC | $368.07 | 2024-2025 | Omvoh, Zepbound |
| Ardelyx, INC. | $297.85 | 2022-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $287.23 | 2023-2025 | Zenpep |
| Gilead Sciences, INC. | $170.52 | 2021-2025 | |
| Redhill Biopharma INC. | $157.00 | 2021-2023 | Talicia, Aemcolo, Movantik |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $119.30 | 2019-2024 | Dificid, Zerbaxa |
| Nestle Healthcare Nutrition INC. | $110.43 | 2021-2023 | |
| Daiichi Sankyo INC. | $106.82 | 2019-2022 | |
| Exact Sciences Corporation | $102.60 | 2025 | Cologuard Collection Kit |
| Ferring Pharmaceuticals INC. | $66.52 | 2020-2023 | Rebyota |
| Orphalan INC | $46.79 | 2024-2025 | Cuvrior |
| Ipsen Biopharmaceuticals, INC | $34.63 | 2025 | Iqirvo |
| Vivus LLC | $34.01 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $33.78 | 2022-2023 | Dupixent |
| Organon LLC | $29.06 | 2023-2024 | Hadlima, Renflexis |
| Braintree Laboratories, INC. | $26.85 | 2020-2023 | Sutab |
| Intercept Pharmaceuticals, INC. | $26.39 | 2020-2021 | |
| Novo Nordisk INC | $16.45 | 2025 | Wegovy |
| Pacira Pharmaceuticals Incorporated | $15.69 | 2023 | Iovera, Exparel |
| Allergan, INC. | $14.99 | 2019 | |
| Ucb, INC. | $14.23 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.21 | 2019 | |
| Blueprint Medicines Corporation | $13.80 | 2024 | Ayvakit |
| Romark Laboratories, Lc | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Penn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.